BioNTech upgraded to buy at Goldman Sachs on tumor asset

BioNTech headquarters with company flags, German biotechnology company, BioNTech Manufacturing, development and production active immunotherapeutic agents in Mainz, Germany - September 7, 2024

Victor Golmer/iStock Editorial via Getty Images

  • Goldman Sachs has upgraded BioNTech (NASDAQ:BNTX) to buy citing the potential of bispecific antibody BNT327 to treat various types of tumors.
  • The firm has a price target of $137 (~27% upside based on Nov. 7 close).
  • Analyst Chris Shibutani said

Leave a Reply

Your email address will not be published. Required fields are marked *